Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,621 to 4,640 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Sustained Care vs Standard Care: serious adverse events | 216 of 680 224 of 677 | -1.3 points -6.3 to 3.7 | 1,357 | NCT01714323 Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers |
| LY2605541 + Insulin Lispro vs Insulin Glargine + Insulin Lispro: Number of Participants With Change in Anti-LY2605541 Antibodies From Baseline to 26 Weeks | 152 of 682 161 of 672 | -1.7 points -6.2 to 2.8 | 1,354 | NCT01468987 A Study in Participants With Type 2 Diabetes Mellitus |
| Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants Who Received Treatment for mCRPC and mCSPC | 668 of 795 536 of 558 | -12.0 points -15.0 to -9.0 | 1,353 | NCT05701007 Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland |
| Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants With Symptomatic Skeletal-Related Event (SSRE) | 44 of 795 43 of 558 | -2.2 points -5.0 to 0.5 | 1,353 | NCT05701007 Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland |
| Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants With Orchiectomy | 10 of 795 9 of 558 | -0.4 points -1.9 to 0.9 | 1,353 | NCT05701007 Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland |
| Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants With de Novo Metastasis | 444 of 795 240 of 558 | 12.8 points 7.4 to 18.1 | 1,353 | NCT05701007 Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland |
| Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants Who Were on Opioids | 310 of 795 332 of 558 | -20.5 points -25.7 to -15.1 | 1,353 | NCT05701007 Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland |
| Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants Undergone Palliative Radiology | 222 of 795 187 of 558 | -5.6 points -10.6 to -0.6 | 1,353 | NCT05701007 Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland |
| Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants Who Were on Bone Medication | 154 of 795 292 of 558 | -33.0 points -37.8 to -27.9 | 1,353 | NCT05701007 Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland |
| Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: deaths from any cause | 343 of 795 218 of 558 | 4.1 points -1.3 to 9.3 | 1,353 | NCT05701007 Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland |
| Denosumab 60 mg Q6M vs Placebo: Number of Participants With a New Vertebral Fracture Through Month 36 | 10 of 679 26 of 673 | -2.4 points -4.3 to -0.7 | 1,352 | NCT00089674 AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer |
| Nintedanib vs Placebo: serious adverse events | 379 of 902 157 of 450 | 7.1 points 1.6 to 12.5 | 1,352 | NCT01015118 LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Clinical Cure at EOT Days the Clinically Evaluable (CE-EOT) Populations | 673 of 677 665 of 674 | 0.7 points -0.4 to 2.0 | 1,351 | NCT03788967 Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) |
| HRV PCV-free Liq Group vs HRV Lyo Group: Number of Subjects With Any Unsolicited AEs | 201 of 677 206 of 674 | -0.9 points -5.8 to 4.0 | 1,351 | NCT03954743 Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks |
| HRV PCV-free Liq Group vs HRV Lyo Group: Number of Subjects With Any Serious Adverse Events (SAEs) | 39 of 677 38 of 674 | 0.1 points -2.4 to 2.6 | 1,351 | NCT03954743 Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks |
| HRV PCV-free Liq Group vs HRV Lyo Group: serious adverse events | 39 of 677 38 of 674 | 0.1 points -2.4 to 2.6 | 1,351 | NCT03954743 Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks |
| Nitazoxanide vs Placebo: serious adverse events | 3 of 686 6 of 663 | -0.5 points -1.6 to 0.5 | 1,349 | NCT04359680 Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection |
| TDF/FTC vs Placebo: Incidence of HSV-2 During the Follow-up Period | 65 of 671 60 of 676 | 0.8 points -2.3 to 3.9 | 1,347 | NCT00458393 Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men |
| MAGE-A3 Group vs Placebo Group: Number of Subjects With Potential Immune-mediated Diseases (pIMDs) | 33 of 895 23 of 450 | -1.4 points -4.1 to 0.8 | 1,345 | NCT00796445 A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor |
| MAGE-A3 Group vs Placebo Group: Number of Subjects With Any Serious Adverse Events (SAEs) | 129 of 895 64 of 450 | 0.2 points -3.9 to 4.0 | 1,345 | NCT00796445 A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor |
Code
curl "https://conductscience.org/api/comparisons/v1?page=232"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=232
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01714323-sae",
"title": "Sustained Care vs Standard Care: serious adverse events",
"summary": "216 of 680 against 224 of 677; risk difference -1.3 points, 95% interval -6.3 to 3.7; NCT01714323, Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers",
"record": "/library/comparisons/NCT01714323-sae",
"nct_id": "NCT01714323",
"kind": "serious-adverse-events",
"participants": 1357,
"risk_difference": {
"value": -0.013224433052393791,
"lower": -0.06288945848082331,
"upper": 0.03652187124851847
},
"group_1": "216 of 680",
"group_2": "224 of 677",
"difference": "-1.3 points",
"interval": "-6.3 to 3.7",
"trial_title": "Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers"
},
{
"id": "NCT01468987-096d7456",
"title": "LY2605541 + Insulin Lispro vs Insulin Glargine + Insulin Lispro: Number of Participants With Change in Anti-LY2605541 Antibodies From Baseline to 26 Weeks",
"summary": "152 of 682 against 161 of 672; risk difference -1.7 points, 95% interval -6.2 to 2.8; NCT01468987, A Study in Participants With Type 2 Diabetes Mellitus",
"record": "/library/comparisons/NCT01468987-096d7456",
"nct_id": "NCT01468987",
"kind": "outcome",
"participants": 1354,
"risk_difference": {
"value": -0.016709433040078214,
"lower": -0.06158025772037633,
"upper": 0.028193633276980545
},
"group_1": "152 of 682",
"group_2": "161 of 672",
"difference": "-1.7 points",
"interval": "-6.2 to 2.8",
"trial_title": "A Study in Participants With Type 2 Diabetes Mellitus"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=233",
"request_id": "A0ECszlwUcJMmr38"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant